Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, 8380453, Santiago, Chile.
Departamento de Cirugía Oriente, Faculty of Medicine, Universidad de Chile, 8380453, Santiago, Chile.
BMC Cancer. 2018 Mar 2;18(1):243. doi: 10.1186/s12885-018-4147-6.
Gallbladder cancer (GBC), although infrequent in industrialized countries, has high incidence rates in certain world regions, being a leading cause of death among elderly Chilean women. Surgery is the only effective treatment, and a five-year survival rate of advanced-stage patients is less than 10%. Hence, exploring immunotherapy is relevant, although GBC immunogenicity is poorly understood. This study examined the relationship between the host immune response and GBC patient survival based on the presence of tumor-infiltrating lymphocytes at different disease stages.
Tumor tissues from 80 GBC patients were analyzed by immunohistochemistry for the presence of CD3, CD4, CD8, and Foxp3 T cell populations, and the results were associated with clinical stage and patient survival.
The majority of tumor samples showed CD3 T cell infiltration, which correlated with better prognosis, particularly in advanced disease stages. CD8, but not CD4, T cell infiltration correlated with improved survival, particularly in advanced disease stages. Interestingly, a < 1 CD4/CD8 T cell ratio was related with increased survival. Additionally, the presence of Foxp3 T cells correlated with decreased patient survival, whereas a ≤ 1 Foxp3/CD8 T cell ratio was associated with improved patient survival.
Depending on the disease stage, the presence of CD8 and absence of Foxp3 T cell populations in tumor tissues correlated with improved GBC patient survival, and thus represent potential markers for prognosis and management of advanced disease, and supports testing of immunotherapy.
胆囊癌(GBC)在工业化国家虽然不常见,但在某些世界地区发病率很高,是智利老年女性死亡的主要原因之一。手术是唯一有效的治疗方法,晚期患者的五年生存率不到 10%。因此,探索免疫疗法是相关的,尽管 GBC 的免疫原性了解甚少。本研究基于不同疾病阶段肿瘤浸润淋巴细胞的存在,探讨了宿主免疫反应与 GBC 患者生存之间的关系。
通过免疫组织化学分析 80 名 GBC 患者肿瘤组织中 CD3、CD4、CD8 和 Foxp3 T 细胞群的存在,并将结果与临床分期和患者生存相关联。
大多数肿瘤样本显示 CD3 T 细胞浸润,与预后较好相关,特别是在晚期疾病阶段。CD8,但不是 CD4,T 细胞浸润与生存改善相关,特别是在晚期疾病阶段。有趣的是,<1 的 CD4/CD8 T 细胞比值与生存率提高相关。此外,Foxp3 T 细胞的存在与患者生存时间缩短相关,而≤1 的 Foxp3/CD8 T 细胞比值与患者生存时间延长相关。
根据疾病阶段,肿瘤组织中 CD8 和 Foxp3 T 细胞群的存在与 GBC 患者生存改善相关,因此可能是预后和晚期疾病管理的潜在标志物,并支持免疫疗法的检测。